Ladies and gentlemen, meet Wockhardt Ltd — the pharma company that has survived USFDA nightmares, import alerts, debt mountains, and Chapter 7 drama… and still shows up to work with a 207 P/E badge.
In Q3 FY26, revenue rose 23% YoY and profit exploded 384%. The market went: “Finally!” But then it saw the balance sheet and said: “Hmm… let’s not get carried away.”
So is this the antibiotic innovator India deserves? Or is the market pricing in a Nobel Prize already?
Let’s dissect.
2. Introduction – Pharma, Pain & Redemption Arcs
Wockhardt isn’t your typical generic drug story.
It’s not just about paracetamol margins and US price erosion.
This is a company that:
Got hammered by USFDA between FY14–FY17
Faced import alerts
Shifted US manufacturing to contract mode
Shut Illinois facility
Took a ₹97 crore deconsolidation hit
Filed Chapter 7 exit for US generics
And still says: “Wait till you see my antibiotic pipeline.”
Now that’s cinematic.
The company operates 12 manufacturing facilities across India, UK, Ireland, and Dubai. It runs two R&D centers (India and UK), with 350+ scientists and 3,264 patents filed.
It’s among the top 3 Indian generics in the UK and 6th largest supplier in Ireland. India contributes 22% revenue, UK 37%, EU 13%, USA 5%, and RoW 23%.
Translation: US exposure is now tiny. That’s deliberate.
But here’s the real twist — they’re not just selling generics.
They are building new chemical entities (NCEs) like Zaynich and Miqnaf. And that’s where things get spicy.
Question for you: When was the last time an Indian pharma company seriously attempted global antibiotic innovation at this scale?
Exactly.
3. Business Model – WTF Do They Even Do?
Let’s simplify.
Wockhardt has 4 big pillars:
1️ Generics Business
Orals, injectables, topicals. Mainly UK, Ireland, EU, India.
Stable. Competitive. Margin-sensitive.
2️ Biosimilars
Focused on anti-diabetic space. Grew 46% YoY in H1 FY25. Expansion planned in Russia, Malaysia, Brazil, Saudi Arabia.
Insulin analogs coming soon.
3️ Novel Antibiotics
This is the hero storyline.
Six drugs received QIDP status from USFDA:
WCK 771
WCK 2349
WCK 4873 (Miqnaf)
WCK 5222 (Zaynich)
WCK 6777
WCK 4282
Zaynich (WCK 5222) completed global Phase III in cUTI and showed superiority vs meropenem. EMA granted accelerated assessment. US FDA accepted NDA.
Miqnaf Phase III in pneumonia completed. WCK 6777 completed Phase I.
